William A. Scott

William A. Scott

Auto-generated profile, based on publicly available information

William A. Scott

C4 Therapeutics, Inc., Watertown, Massachusetts

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
WSWilliam A. Scott
William A. Scott
EDErum Z. Dhanji
Erum Z. Dhanji
BDBoris J. A. Dyakov
Boris J. A. Dyakov
EDEma S. Dreseris
Ema S. Dreseris
JAJonathon S. Asa
Jonathon S. Asa
ECEric Campos
Eric Campos
The ATRX ATP-dependent chromatin remodelling/helicase protein associates with the DAXX histone chaperone to deposit histone H3.3 over repetitive DNA regions. Because ATRX-protein interactions impart functions, such as histone deposition, we used proximity-dependent biotinylation (BioID) to identify proximal associations for ATRX. The proteomic screen captured known interactors, such as DAXX, NBS1, and PML, but also identified a range of new associating proteins. To gauge the scope of their roles, we examined three novel ATRX-associating proteins that likely differed in function, and for which little data were available. We found CCDC71 to associate with ATRX, but also HP1 and NAP1, suggesting a role in chromatin maintenance. Contrastingly, FAM207A associated with proteins involved in ribosome biosynthesis and localized to the nucleolus. ATRX proximal associations with the SLF2 DNA damage response factor help inhibit telomere exchanges. We further screened for the proteomic changes at telomeres when ATRX, SLF2, or both proteins were deleted. The loss caused important changes in the abundance of chromatin remodelling, DNA replication, and DNA repair factors at telomeres. Interestingly, several of these have previously been implicated in alternative lengthening of telomeres. Altogether, this study expands the repertoire of ATRX-associating proteins and functions.

28 October 2025 in Cancer Research
Verified
Journal Article
Closed access
BKBridget T. Kreger
Bridget T. Kreger
YLYanke Liang
Yanke Liang
NRNicole M. Reilly
Nicole M. Reilly
MSMeghan E. Spears
Meghan E. Spears
WSWilliam A. Scott
William A. Scott
MSMathew E. Sowa
Mathew E. Sowa
Currently approved BRAF inhibitors (BRAFi) have achieved impressive efficacy in BRAFV600-mutant cancers. However, the clinical benefit of BRAFis is limited by several factors, including vulnerability to RAF dimer–driven resistance mechanisms, poor brain penetration, and side effects arising from paradoxical activation of MAPK signaling in normal tissue. In this study, we aimed to overcome these limitations by developing CFT1946, a potent, orally bioavailable, and brain-penetrant cereblon-based bifunctional degrader that targets BRAFV600-mutant protein while sparing wild-type RAF family members. CFT1946 demonstrated potent activity in preclinical models of BRAFV600-mutant driven melanoma and colorectal cancer while sparing wild-type MAPK signaling and mitigating the paradoxical activation associated with approved BRAFis. CFT1946 was efficacious in an intracranial BRAFV600E melanoma tumor model and demonstrated robust activity in multiple cellular and patient-derived BRAFV600-mutant melanoma and colorectal cancer models of acquired and adaptive RAF dimer–driven BRAFi resistance. CFT1946 therefore represents an effective therapeutic modality with the potential to overcome the key limitations of current BRAFV600-mutant targeted therapies. Significance: CFT1946 is a clinical stage, orally available, brain-penetrant BRAFV600-mutant protein degrader that overcomes RAF dimer–driven resistance mechanisms to currently approved BRAF inhibitors and represents a promising approach to treating BRAFV600-mutant tumors. See related commentary by Chen and Bollag, p. 289